Pulmonx (LUNG)
NASDAQ:LUNG
Want to see LUNG full AI Analyst Report?
LUNG Stock Chart & Stats
$1.80
-$0.17(-2.57%)
At close: 4:00 PM EST
$1.80
-$0.17(-2.57%)
Day’s Range― - ―
52-Week Range$1.13 - $3.88
Previous CloseN/A
Volume95.69K
Average Volume (3M)308.20K
Market Cap
$68.00M
Enterprise Value$64.41M
Total Cash (Recent Filing)$61.57M
Total Debt (Recent Filing)$56.29M
Price to Earnings (P/E)―
Beta1.25
Next Earnings
Aug 05, 2026EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.30
Shares Outstanding42,237,200
10 Day Avg. Volume245,979
30 Day Avg. Volume308,202
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)1.66
Price to Sales (P/S)0.99
P/FCF Ratio-2.73
Enterprise Value/Market Cap0.95
Enterprise Value/Revenue0.73
Enterprise Value/Gross Profit0.96
Enterprise Value/Ebitda-1.31
Forecast
1Y Price Target
$3.50Price Target Upside94.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.14
Revenue Forecast (FY)$90.87M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained mid-70% gross margins reflect strong unit economics for single-use valves and consumables. Durable margin strength provides a structural buffer to support R&D, clinical investment and commercial scaling, improving odds of eventual operating leverage as revenue recovers.
Per-Procedure Recurring Revenue ModelA procedure-driven, consumable-heavy model creates recurring, volume-linked revenue that scales with treating center adoption. Durable demand from repeat procedures and training/proctoring programs supports predictable long-term unit growth if clinical adoption continues.
Clinical Pipeline Expands TAMProgress in the CONVERT II pivotal trial for AeriSeal represents a structural growth lever: successful approval would broaden patient eligibility and diversify product mix. A ~20% TAM expansion materially improves long-run revenue potential and reduces single-product concentration risk.
Bears Say
Negative Cash Flow And Ongoing Cash BurnConsistent negative operating and free cash flow means the company cannot self-fund growth. Reliance on external financing or credit facilities increases dilution and refinancing risk, constraining long-term investment flexibility and raising runway sensitivity to execution slippage.
Rising Leverage And Weakened Balance SheetDebt exceeding equity and shrinking equity reduce financial flexibility and increase covenant and liquidity risk. Higher leverage raises fixed obligations, limits strategic optionality, and amplifies downside if revenue recovery is delayed or clinical/regulatory setbacks occur.
Revenue Decline And Execution DependenceYear-over-year revenue decline signals demand weakness and exposes sensitivity to distributor/regulatory disruptions. Management's return-to-growth hinges on salesforce ramp (6–9 months) and China registration timing, creating execution risk that could delay realizing operating leverage.
Pulmonx News
LUNG FAQ
What was Pulmonx’s price range in the past 12 months?
Pulmonx lowest stock price was $1.13 and its highest was $3.88 in the past 12 months.
What is Pulmonx’s market cap?
Pulmonx’s market cap is $68.00M.
When is Pulmonx’s upcoming earnings report date?
Pulmonx’s upcoming earnings report date is Aug 05, 2026 which is in 63 days.
How were Pulmonx’s earnings last quarter?
Pulmonx released its earnings results on Apr 29, 2026. The company reported -$0.33 earnings per share for the quarter, missing the consensus estimate of -$0.327 by -$0.003.
Is Pulmonx overvalued?
According to Wall Street analysts Pulmonx’s price is currently Undervalued.
Does Pulmonx pay dividends?
Pulmonx does not currently pay dividends.
What is Pulmonx’s EPS estimate?
Pulmonx’s EPS estimate is -0.28.
How many shares outstanding does Pulmonx have?
Pulmonx has 42,237,200 shares outstanding.
What happened to Pulmonx’s price movement after its last earnings report?
Pulmonx reported an EPS of -$0.33 in its last earnings report, missing expectations of -$0.327. Following the earnings report the stock price went up 6.667%.
Which hedge fund is a major shareholder of Pulmonx?
Currently, no hedge funds are holding shares in LUNG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pulmonx Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.50 (94.44% Upside)
$3.50 (94.44% Upside)
Hedge Fund Trend
Decreased
By 2.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $140.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 5.8%
Last 30 Days ▼ 5.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-74.30%
12-Months-Change
Fundamentals
Return on Equity
-82.79%
Trailing 12-Months
Asset Growth
-20.13%
Trailing 12-Months
Company Description
Pulmonx
Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
LUNG Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call mixes clear near-term challenges (Q1 revenue declines, China registration-driven international disruption, ongoing net losses) with several meaningful positive developments: improved gross margin, cost reductions lowering operating expense trajectory, strengthened liquidity via a $60M credit facility, addition of U.S. treating centers and filled sales roles, and progressing pivotal clinical enrollment that could expand TAM by ~20%. Management reiterated full-year guidance of $90M–$92M and expects sequential improvement with a return to growth in H2 2026. The narrative is execution- and timing-dependent but supported by concrete operational and financial actions that materially reduce downside risk.View all LUNG earnings summariesLUNG Stock 12 Month Forecast
Average Price Target
$3.50
▲(94.44% Upside)
Technical Analysis
Apyx Medical
―
Xtant Medical Holdings
―
Sensus Healthcare
―
TELA Bio
―
Icecure Medical
―
Ownership Overview
13.71% Insiders
17.24% Mutual Funds
31.62% Other Institutional Investors
29.48% Public Companies and
Individual Investors